EIRY ROBERTS - 08 Nov 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role: Chief Medical Officer
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol: NBIX
Transactions as of: 08 Nov 2024
Net transactions value: +$599,873
Form type: 4
Filing time: 12 Nov 2024, 17:58:47 UTC
Previous filing: 07 Jun 2024
Next filing: 19 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBIX	Common Stock	Options Exercise	$399,943	+5,140	+22%	$77.81	28,856	08 Nov 2024	Direct	F1
transaction	NBIX	Common Stock	Options Exercise	$99,935	+1,233	+4.3%	$81.05	30,089	08 Nov 2024	Direct	F1
transaction	NBIX	Common Stock	Options Exercise	$99,916	+971	+3.2%	$102.90	31,060	08 Nov 2024	Direct	F1
transaction	NBIX	Common Stock	Options Exercise	$79.02	+1	+0%	$79.02	31,061	08 Nov 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBIX	Incentive Stock Option	Options Exercise	$0	-5,140	-100%	$0.000000	0	08 Nov 2024	Common Stock	5,140	$77.81	Direct	F3
transaction	NBIX	Incentive Stock Option	Options Exercise	$0	-1,233	-100%	$0.000000	0	08 Nov 2024	Common Stock	1,233	$81.05	Direct	F4
transaction	NBIX	Incentive Stock Option	Options Exercise	$0	-971	-100%	$0.000000	0	08 Nov 2024	Common Stock	971	$102.90	Direct	F5
transaction	NBIX	Incentive Stock Option	Options Exercise	$0	-1	-0.08%	$0.000000	1,265	08 Nov 2024	Common Stock	1	$79.02	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2	29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
F3	Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
F4	Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
F5	Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
F6	Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.